Key facts
- It has raised $500K; the latest was Early Stage VC in May 2025.
- Notable investors include Y Combinator, Vento, Lombardstreet Ventures, Skarlo.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Nucleo (Decision/Risk Analysis)
- ·The full record, as it builds
Funding rounds
No funding rounds for Nucleo (Decision/Risk Analysis) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nucleo (Decision/Risk Analysis)
Developer of an artificial intelligence-based detection technology designed to improve cancer treatment decisions. The company's technology facilitates sarcopenia detection, tumor lesion sizing, and target and non-target lesion classification, enabling medical professionals to make precision oncology accessible to every patient.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 4
- Website
- nucleoresearch.com/
- Ownership
- Privately Held (backing)
Nucleo (Decision/Risk Analysis) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nucleo (Decision/Risk Analysis) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nucleo (Decision/Risk Analysis) in its N-PORT filings yet. We sweep new filings monthly.